Вы находитесь на странице: 1из 3

TINJAUAN PUSTAKA

1. Ilmu Penyakit Kulit dan Kelamin FK UI Hal.213


2. Nestle FO, Kaplan DH, Barker J. Mechanism of disease psoriasis. N Eng J Med [Internet].
2009. [cited 2015 Jan 24]; 361: 496-509. Available from:
http://www.nejm.org/doi/pdf/10.1056/NEJMra0804595
3. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA,
Paller AS, Leff ell DJ, editors. Fitzpatricks dermatology in general medicine. 7th ed. United
States of America: McGraw Hill; 2008: 169-93.
4. Stern RS. Psoralen and ultraviolet A light therapy for psoriasis. N Eng J Med [Internet]. 2007
[cited 2015 Jan 24]; 357: 682-90. Available from:
http://www.nejm.org/doi/full/10.1056/NEJMct072317
5.Krueger GG. Psoriasis therapy-observational or rational? N Eng J Med [Internet]. 1993 Jun
24 [cited 2015 Jan 24]; 328(25): 1845-6. Available from
http://www.nejm.org/doi/pdf/10.1056/ NEJM199306243282511
6. Ilmu Penyakit Kulit dan Kelamin FK UI Hal.214
7. Whan B. Kim, Dana Jerome, Jensen Yeung. Diagnosis and management of psoriasis. Vol
63: April 2017. Can Fam Physician 2017;63: 278-85
8.AFSHAR M, MARTINEZ AD, GALLO RL et al.: Induction and exacerbation of psoriasis
with interferon- therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad
Dermatol Venereol 2013; 27: 771-8
9.W. Alwan, F.O. Nestle. Pathogenesis and treatment of psoriasis: exploiting
pathophysiological pathways for precision medicine . Clin Exp Rheumatol 2015; 33 (Suppl.
93): S2-S6.
10.Huang X, Tanojo H, Lenn J, Deng CH, Krochmal L. A novel foam vehicle for delivery of
topical corticosteroids. J Am Acad Dermatol. 2005;53(1 suppl 1):S26-S38.
11.National Psoriasis Foundation (NPF). Topical steroids potency chart.
https://www.psoriasis.org/about-psoriasis/treatments/topicals/steroids/potency-chart.
Accessed January 9, 2016.
12.Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: An updated
practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol.
2004;93(3 suppl 2):S1-S21
13.Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am.
2004;24(4):631-644, vi-vii.
14.Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: An updated
practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol.
2004;93(3 suppl 2):S1-S21.
15.Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: A
systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol.
2012;26(suppl 3):36-46. 22.
16.Levin E, Gupta R, Butler D, Chiang C, Koo JY. Topical steroid risk analysis: Differentiating
between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014;25(6):501-
506.
17.Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in
pregnancy: A population-based cohort study. J Invest Dermatol. 2011;131(4):884-891.
18.Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am
Acad Dermatol. 1983;9(1):59-65
19.Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.
J Drugs Dermatol. 2009;8(4):351-357.
20.McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-
psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial
membrane potential, and induces apoptosis through a pathway dependent on respiratory
competent mitochondria. FASEB J. 2005;19(8):1012-1014.
21.Stern RS: Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med.
2007;357(7):68290. 10.1056/NEJMct072317 [PubMed] [Cross Ref]
22.Hnigsmann H: Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26(4):34350.
10.1046/j.1365-2230.2001.00828.x [PubMed] [Cross Ref]
23.Danno K, Toda K, Horio T: Ultraviolet-B radiation suppresses mast cell degranulation
induced by compound 48/80. J Invest Dermatol. 1986;87(6):7758
24.Bagel J: Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of
moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):36671. [PubMed]
25.Wolf P, Hofer A, Weger W, et al. : 311 nm ultraviolet B-accelerated response of psoriatic
lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed.
2011;27(4):1869. 10.1111/j.1600-0781.2011.00594.x [PubMed] [Cross Ref]
26.Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E.
BIOLOGICAL THERAPY OF PSORIASIS. Indian Journal of Dermatology. 2010;55(2):161-
170. doi:10.4103/0019-5154.62754.
27.M.D Colombo, N. Cassano, G.Bella and G. A. Vena. Cyclosporine Regimens in Plaque
Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment
Approches. Volume 2013, Article ID 805705, 11 pages.
http://dx.doi.org/10.1155/2013/805705
28.Stef P. MENTING, Paul M. DEKKER, Jacqueline LIMPENS,Lotty HOOFT and Phyllis I.
SPULS. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the
Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic
Acid Supplementation. Acta Derm Venereol 2016; 96: 2328.
29.Rashmi Sarkar, Shikha Chugh, Vijay K Garg. Acitretin in dermatology2013. 79 Issue 6,
759-771. Department of Dermatology, Maulana Azad Medical College, New Delhi, India
30. Ilmu penyakit kulit dan kelamin FK UI. Edisi ketujuh. Hal 217-218
31. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.